Education
About Us
Working with TipRanks
Follow Us
Elite Pharmaceuticals (ELTP)
OTHER OTC:ELTP
RESEARCH TOOLSreports
Total Valuation
Elite Pharmaceuticals has a market cap or net worth of $552.40M. The enterprise value is $623.58M.
Market Cap$552.40M
Enterprise Value$623.58M
Share Statistics
Elite Pharmaceuticals has 1,068,463,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,068,463,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Elite Pharmaceuticals’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is 1809.64%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)1809.64%
Return on Capital Employed (ROCE)0.23
Revenue Per Employee1.31M
Profits Per Employee-67.42K
Employee Count64
Asset Turnover0.87
Inventory Turnover2.71
Valuation Ratios
The current PE Ratio of Elite Pharmaceuticals is -107.70. Elite Pharmaceuticals’s PEG ratio is -1.91.
PE Ratio-107.70
PS Ratio0.00
PB Ratio11.66
Price to Fair Value8.68
Price to FCF126.55
Price to Operating Cash Flow83.68
PEG Ratio-1.91
Income Statement
In the last 12 months, Elite Pharmaceuticals had revenue of 84.04M and earned -4.31M in profits. Earnings per share was -4.04.
Revenue84.04M
Gross Profit40.09M
Operating Income19.60M
Pretax Income-52.14K
Net Income-4.31M
EBITDA2.84M
Earnings Per Share (EPS)-4.04
Cash Flow
In the last 12 months, operating cash flow was 7.46M and capital expenditures -2.53M, giving a free cash flow of 4.93M billion.
Operating Cash Flow7.46M
Free Cash Flow4.93M
Free Cash Flow per Share<0.01
Dividends & Yields
Elite Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.87
52-Week Price Change173.68%
50-Day Moving Average0.57
200-Day Moving Average0.51
Relative Strength Index (RSI)36.16
Average Volume (3m)2.34M
Important Dates
Elite Pharmaceuticals upcoming earnings date is Aug 18, 2025, TBA (Confirmed).
Last Earnings DateJun 30, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Elite Pharmaceuticals as a current ratio of 4.88, with Debt / Equity ratio of 20.40%
Current Ratio4.88
Quick Ratio3.50
Debt to Market Cap0.02
Net Debt to EBITDA-0.14
Interest Coverage Ratio25.38
Taxes
In the past 12 months, Elite Pharmaceuticals has paid 4.26M in taxes.
Income Tax4.26M
Effective Tax Rate-81.75
Enterprise Valuation
Elite Pharmaceuticals EV to EBITDA ratio is 163.34, with an EV/FCF ratio of 94.17.
EV to Sales5.52
EV to EBITDA163.34
EV to Free Cash Flow94.17
EV to Operating Cash Flow62.28
Balance Sheet
Elite Pharmaceuticals has $11.32M in cash and marketable securities with $10.91M in debt, giving a net cash position of -$400.50K billion.
Cash & Marketable Securities$11.32M
Total Debt$10.91M
Net Cash-$400.50K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share$0.04
Margins
Gross margin is 47.70%, with operating margin of 23.32%, and net profit margin of -5.13%.
Gross Margin47.70%
Operating Margin23.32%
Pretax Margin-0.06%
Net Profit Margin-5.13%
EBITDA Margin3.38%
EBIT Margin0.86%
Analyst Forecast
The average price target for Elite Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast48.42%
EPS Growth Forecast-120.20%